UK markets open in 4 hours 9 minutes
NIKKEI 225
38,719.35 -227.58 (-0.58%) HANG SENG
19,323.94 +103.32 (+0.54%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,426.00 +0.10 (+0.00%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,086.05 -946.74 (-1.69%)
PreveCeutical Medical Inc. (PREV.CN)
Canadian Sec - Canadian Sec Real-time price. Currency in CAD
Add to watchlist
At close: 01:59PM EDT
| Previous close | 0.0250 |
| Open | 0.0200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0200 - 0.0200 |
| 52-week range | 0.0150 - 0.0300 |
| Volume | |
| Avg. volume | 221,333 |
| Market cap | 13.383M |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswirePREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM
PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that it has started preparations to accelerate completion of its preclinical dual gene therapy program using our developed and in vitro validated Smart-siRNA sequences, which when paired with our proprietary bioresponsive lipid-nanoparticulate delivery systems (US patent no. 11,566,044) effectively target the PTPN1 gene.
© 2024 Yahoo. All rights reserved.